ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock

Rhea-AI Summary

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has successfully completed its underwritten public offering, selling 1,500,000 shares at $50.00 each, generating gross proceeds of $75 million. Underwriters have a 30-day option to buy an additional 225,000 shares. Guggenheim Securities and Raymond James served as book-running managers. The offering was made under a shelf registration statement filed with the SEC. ANI focuses on developing high-quality branded and generic pharmaceuticals, particularly in niche areas such as oncology and controlled substances.

Positive

• Gross proceeds from the offering amount to $75 million.
• The underwriters' option to purchase an additional 225,000 shares could further bolster funds.

Negative

• The public offering may lead to shareholder dilution.

BAUDETTE, Minn.--(BUSINESS WIRE)-- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (ANI or the Company) today announced the closing of its previously announced underwritten public offering. A total of 1,500,000 shares of its common stock were sold at a public offering price of $50.00 per share. The gross proceeds of the offering to the Company are $75 million, before deducting the underwriting discounts and commissions and offering expenses. In addition, ANI granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Guggenheim Securities acted as lead book-running manager for the offering. Raymond James also acted as book-running manager for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.

The securities described above were offered by ANI pursuant to a shelf registration statement on Form S-3 (File No. 333-239771), which was filed by the Company with the Securities and Exchange Commission (SEC) on July 9, 2020 and was declared effective by the SEC on July 17, 2020.

A preliminary prospectus supplement relating to the offering was filed with the SEC on November 3, 2021 and is available on the SEC’s website at http://www.sec.gov. A final prospectus supplement relating to and describing the terms of the offering was also filed with the SEC and is available on the SEC’s website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com, and from Raymond James & Associates, Inc. Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863 or by email at prospectus@raymondjames.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. We focus on niche and high barrier-to-entry opportunities including controlled substances, oncology products (anti-cancers), hormones and steroids, and complex formulations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211108006059/en/

Investor Relations:

Lisa M. Wilson, In-Site Communications, Inc.

T: 212-452-2793

E: lwilson@insitecony.com

Source: ANI Pharmaceuticals, Inc.

FAQ

What is the recent public offering by ANI Pharmaceuticals?

ANI Pharmaceuticals closed a public offering of 1,500,000 shares at $50.00 per share, raising $75 million.

When did ANI Pharmaceuticals announce its public offering?

The announcement was made on November 8, 2021.

Who were the underwriters for ANI Pharmaceuticals' offering?

Guggenheim Securities and Raymond James acted as book-running managers for the offering.

How does the offering impact shareholders of ANIP?

The offering could lead to dilution of existing shareholders' equity.

What niche markets does ANI Pharmaceuticals focus on?

ANI specializes in high barrier-to-entry opportunities, including oncology products and controlled substances.